SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gufic Biosciences - Quaterly Results

29 May 2024 Evaluate
The revenue for the March 2024 quarter is pegged at Rs. 1949.94 millions, about 12.69% up against Rs. 1730.36 millions recorded during the year-ago period.A slim rise of 10.73% was recorded in the Net profit for the quarter ended March 2024 to Rs. 200.47  millions  From Rs. 181.05 millions.OP of the company witnessed a marginal growth to 351.09 millions from 327.72 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 1949.94 1730.36 12.69 8066.66 6906.21 16.80 8066.66 6906.21 16.80
Other Income 8.81 6.23 41.41 21.77 25.74 -15.42 21.77 25.74 -15.42
PBIDT 351.09 327.72 7.13 1480.48 1372.25 7.89 1480.48 1372.25 7.89
Interest 36.47 29.22 24.81 153.60 82.23 86.79 153.60 82.23 86.79
PBDT 314.62 298.50 5.40 1326.88 1290.02 2.86 1326.88 1290.02 2.86
Depreciation 43.42 59.18 -26.63 170.17 222.81 -23.63 170.17 222.81 -23.63
PBT 271.20 239.32 13.32 1156.71 1067.21 8.39 1156.71 1067.21 8.39
TAX 70.73 58.27 21.38 295.36 270.16 9.33 295.36 270.16 9.33
Deferred Tax -2.27 -3.73 -39.14 31.66 -11.94 -365.16 31.66 -11.94 -365.16
PAT 200.47 181.05 10.73 861.35 797.05 8.07 861.35 797.05 8.07
Equity 100.28 96.94 3.45 100.28 96.94 3.45 100.28 96.94 3.45
PBIDTM(%) 18.01 18.94 -4.93 18.35 19.87 -7.63 18.35 19.87 -7.63

Gufic Biosciences Share Price

306.05 4.85 (1.61%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×